54 results
8-K
EX-99.1
ONCR
Oncorus, Inc.
22 May 23
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
4:13pm
compared to $62.2 million as of December 31, 2022.
Research and development expenses for the quarter ended March 31, 2023 were $10.6 million compared … impairment charge of $14.6 million taken on March 31, 2023 and lower research and development and general and administrative expenses, as described above
8-K
EX-99.1
ONCR
Oncorus, Inc.
2 Nov 22
Oncorus Reports Third Quarter 2022 Financial Results and Provides Business Updates
7:11am
and investments totaled $81.5 million as of September 30, 2022 compared to $123.9 million as of December 31, 2021.
Research and development expenses … )
Three Months Ended
Nine Months Ended
September 30,
Operating expenses:
Research and development
General and administrative
Total operating expenses
8-K
EX-99.1
2upleibm4gal5sla
4 Aug 22
Oncorus Reports Second Quarter 2022 Financial Results and Provides Business Updates
9:04am
8-K
EX-99.1
he3w2e8b
23 Jun 22
Oncorus Appoints Douglas Fambrough to Board of Directors
7:21am
8-K
EX-99.1
wekpnbqzly3ab87q1c
4 May 22
Oncorus Reports First Quarter 2022 Financial Results and Provides Business Updates
7:15am
8-K
EX-10.1
bjv90
5 Apr 22
Entry into a Material Definitive Agreement
7:10am
8-K
EX-99.1
bgoi3y39
5 Apr 22
Entry into a Material Definitive Agreement
7:10am
8-K
EX-99.1
byowk5q4l4oa3eid 317
9 Mar 22
Oncorus Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
7:46am
424B5
kv7np91wk ar71f2
19 Nov 21
Prospectus supplement for primary offering
4:41pm
S-3
uft7cpy
3 Nov 21
Shelf registration
5:00pm